Home' Australian Pharmacist : Australian Pharmacist March 2016 Contents Australian Pharmacist March 2016 I © Pharmaceutical Society of Australia Ltd.
References from Aged Care article page 32.
1. Ma JD, Lee KC, Kuo GM. Clinical application of
pharmacogenomics. J Pharm Pract 2012;25(4):417–27.
2. Pirmohamed M. Personalized pharmacogenomics:
predicting efficacy and adverse drug reactions. Annu Rev
Genomics Hum Genet 2014;15:349–70.
3. Relling MV, Evans WE. Pharmacogenomics in the clinic.
4. Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B*58:01
genotyping to prevent allopurinol induced severe
cutaneous adverse reactions in Taiwan: national
prospective cohort study. BMJ 2015;351:h4848 doi:
5. Li-Wan-Po A. Pharmacogenetics begins to deliver on its
promises. BMJ 2015;351:h5042 doi: 10.1136/bmj.h5042.
6. Lee MT, Mahasirimongkol S, Zhang Y, et al. Clinical
application of pharmacogenomics: the example of
HLA-based drug-induced toxicity. Public Health Genomics
7. Sukasem C, Puangpetch A, Medhasi S, et al.
Pharmacogenomics of drug-induced hypersensitivity
reactions: challenges, opportunities and clinical
implementation. Asian Pac J Allergy Immunol
8. Braga IL, Silva PN, Furuya TK, et al. Effect of APOE and
CHRNA7 genotypes on the cognitive response to
cholinesterase inhibitor treatment at different stages of
Alzheimer ’s disease. Am J Alzheimers Dis Other Demen
9. Oboudiyat C, Glazer H, Seifan A, et al. Alzheimer’s disease.
Seminars in Neurology 2013;33(4):313–29.
10. Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer’s
Disease: An Update. In: Hyman SE, ed. Annual Review of
Neuroscience, Vol 37, 2014:79–100.
11. Hanson AJ, Craft S, Banks WA. The APOE genotype:
modification of therapeutic responses in Alzheimer’s
disease. Curr Pharm Des 2015;21(1):114–20.
12. Klimkowicz-Mrowiec A, Wolkow P, Sado M, et al. Influence
of rs1080985 single nucleotide polymorphism of the
CYP2D6 gene on response to treatment with donepezil in
patients with Alzheimer’s disease. Neuropsychiatr Dis Treat
13. Allen SJ, MacGowan SH, Tyler S, Wilcock GK, Robertson
AG, Holden PH, et al. Reduced cholinergic function in
normal and Alzheimer’s disease brain is associated with
apolipoprotein E4 genotype. Neurosci Lett 1997;239(1):33–
14. Martinelli-Boneschi F, Giacalone G, Magnani G, et al.
Pharmacogenomics in Alzheimer’s disease: a genome-wide
association study of response to cholinesterase inhibitors.
Neurobiol Aging 2013;34(6):1711 e7–13.
15. Wattmo C, Wallin AK, Londos E, et al. Predictors of long-
term cognitive outcome in Alzheimer’s disease. Alzheimers
Res Ther 2011;3(4):23.
16. Therapeutic Guidelines. Dementia: pharmacological
management. Psychotropic. Revised June 2013.
Therapeutic Guidelines (etg45 Jul 2015).
17. Birks J. Cholinesterase inhibitors for Alzheimer’s disease.
Cochrane Database Syst Rev 2006(1):CD005593.
18. Patterson CE, Todd SA, Passmore AP. Effect of
apolipoprotein E and butyrylcholinesterase genotypes on
cognitive response to cholinesterase inhibitor treatment at
different stages of Alzheimer’s disease. Pharmacogenomics
19. Cacabelos R, Martinez R, Fernandez-Novoa L, Carril JC,
Lombardi V, Carrera I, et al. Genomics of Dementia: APOE-
and CYP2D6-Related Pharmacogenetics. Int J Alzheimers
20. Yang YH, Wu SL, Chou MC, et al. Plasma concentration
of donepezil to the therapeutic response of Alzheimer’s
disease in Taiwanese. J Alzheimers Dis 2011;23(3):391–7 .
21. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4
allele as a predictor of cholinergic deficits and treatment
outcome in Alzheimer disease. Proc Natl Acad Sci USA
22. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings
F, Parys W. APOE genotype: no influence on galantamine
treatment efficacy nor on rate of decline in Alzheimer’s
disease. Dement Geriatr Cogn Disord 2001;12(2):69–77 .
23. Cacabelos R. Pharmacogenomics and therapeutic
prospects in dementia. Eur Arch Psychiatry Clin Neurosci
2008;258 Suppl 1:28–47 .
24. Bachyns’ka N, Rozheliuk IF, Kholyn VO, et al. ApoE gene
polymorphism as a predictor of therapeutic response to
treatment acetylcholinesterase inhibitor for elderly patients
with Alzheimer’s and vascular dementia types. Wiad Lek
2014;67(2 Pt 2):161–5 .
25. Han HJ, Kim BC, Lee JY, et al. Response to rivastigmine
transdermal patch or memantine plus rivastigmine patch
is affected by apolipoprotein E genotype in Alzheimer
patients. Dement Geriatr Cogn Disord 2012;34(3-4):167–73.
26. Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil,
galantamine and rivastigmine in 938 Italian patients with
Alzheimer’s disease: a prospective, observational study. CNS
27. Wang L, Day J, Roe CM, et al. The effect of APOE epsilon4
allele on cholinesterase inhibitors in patients with
Alzheimer disease: evaluation of the feasibility of resting
state functional connectivity magnetic resonance imaging.
Alzheimer Dis Assoc Disord 2014;28(2):122-7 .
28. Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of
tacrine therapy depends on apolipoprotein genotype and
gender of the subjects with Alzheimer ’s disease. Neurology
29. Rigaud AS, Traykov L, Latour F, et al. Presence or absence of
at least one epsilon 4 allele and gender are not predictive
for the response to donepezil treatment in Alzheimer ’s
disease. Pharmacogenetics 2002;12(5):415–20.
30. Kennedy RE, Cutter GR, Schneider LS. Effect of APOE
genotype status on targeted clinical trials outcomes and
efficiency in dementia and mild cognitive impairment
resulting from Alzheimer’s disease. Alzheimers Dement
31. Gilman C, McSweeney C, Mao Y. The applications of
pharmacogenomics to neurological disorders. Curr Mol
Med 2014;14(7):880–90 .
32. Nebes RD, Pollock BG, Perera S, Halligan EM, Saxton JA.
The greater sensitivity of elderly APOE epsilon4 carriers
to anticholinergic medications is independent of
cerebrovascular disease risk. Am J Geriatr Pharmacother
33. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod
HL, Voora D, et al. The clinical pharmacogenomics
implementation consortium: CPIC guideline for SLCO1B1
and simvastatin-induced myopathy. Clin Pharmacol Ther
34. Therapeutic Guidelines. Dyslipidaemia: pharmacological
management. Cardiovascular. Revised Feb 2012.
Therapeutic Guidelines (etg45 July 2015).
35. Magni P, Macchi C, Morlotti B, Sirtori CR, Ruscica M. Risk
identification and possible countermeasures for muscle
adverse effects during statin therapy. Eur J Intern Med
36. Yosef Y, Schurr D, Constantini N. Statins and muscle pain.
Harefuah 2014;153(7):423–7, 31.
37. Gryn SE, Hegele RA. Pharmacogenomics, lipid disorders,
and treatment options. Clin Pharmacol Ther 2014;96(1):36–
38. Hu M, Tomlinson B. Pharmacogenomics of lipid-lowering
therapies. Pharmacogenomics 2013;14(8):981–95.
39. Hopewell JC, Reith C, Armitage J. Pharmacogenomics of
statin therapy: any new insights in efficacy or safety? Curr
Opin Lipidol 2014;25(6):438–45.
40. Yip VL, Pirmohamed M. Expanding role of
pharmacogenomics in the management of cardiovascular
disorders. Am J Cardiovasc Drugs 2013;13(3):151–62.
41. Daly AK. Pharmacogenomics of adverse drug reactions.
Genome Med 2013;5(1):5.
42. Giorgi MA, Caroli C, Arazi HC, et al. Pharmacogenomics and
adverse drug reactions: the case of statins. Expert Opin
Merck restructures Asian
Merck has announced a company restructure
to create a new network in Asia. The changes
will see two new Asia Pacific sub regions
formed as part of five divisions in Asia:
Asia Pacific Sub-region 1: Developed
Markets to include Australia, New
Zealand (NZ), Hong Kong, Korea and
Asia Pacific Sub-region 2: Emerging
Markets to include Indonesia, Singapore,
Malaysia, Thailand, Philippines, Vietnam
Managing Director of Australia and NZ,
Andre Musto, has been promoted to lead the
Asia Pacific Developed Markets Sub-region
1, effective 1 March. He will continue to lead
the Australian and New Zealand operations
until a successor is appointed.
Mr Musto was Managing Director at Merck
for two years having previously worked
with AstraZeneca locally, regionally and
globally for a number of years. He intends
to relocate with his family to Singapore in
the coming months.
‘I am very proud of the team and the
achievements of Merck’s Australia and New
Zealand business despite a challenging
external environment, ,’ Mr Musto said.
‘Merck is the leading provider of IVF
products in Australia and NZ and has key
products in the Oncology and Multiple
Sclerosis portfolios. Merck has a very
exciting pipeline of new therapies in areas
focussed in Oncology, Immuno-oncology,
Immunology and Neurodegenerative
diseases, all areas of unmet clinical need.
Links Archive Australian Pharmacist February 2016 Australian Pharmacist April 2016 Navigation Previous Page Next Page